| Literature DB >> 32522583 |
Thazin Shwe1, Cherry Bo-Htay1, Tom Leech2, Benjamin Ongnok1, Thidarat Jaiwongkum2, Sasiwan Kerdphoo2, Siripong Palee2, Wasana Pratchayasakul1, Nipon Chattipakorn1, Siriporn C Chattipakorn3.
Abstract
Largely as a consequence of changes in modern lifestyle, a significant proportion of global population have become obese. When obese people grow old, pathologies aggravate neurodegeneration. Several studies have demonstrated that both aging and obesity have deleterious impact on brain. However, the time course effects of combined aging-induced by d-galactose and obesity caused by high-fat diet on cognitive and brain function have not been explored. We hypothesize that D-galactose accelerates and aggravates brain pathologies and cognitive dysfunction in the state of obesity. Ninety-six Wistar rats were separated into two groups to be fed with either a normal diet (ND) or a high-fat diet (HFD) for 16 to 20 weeks. At the end of 12 weeks, ND and HFD-fed rats were injected with vehicle (0.9% NSS, s.c) or d-galactose (150 mg/kg/d, s.c) for 4 or 8 weeks. Data from behavioral test, metabolic parameters and brain pathologies were determined at 4 and 8-weeks after d-galactose administration. The results from both d-galactose-treated rats and HFD-fed rats showed that there was an equal increase in advanced glycation end products, and microglial activation, and an impairment in long-term depression, long-term potentiation, and synaptic protein and dendritic spine density in hippocampus, resulting in cognitive decline. However, d-galactose did not accelerate or aggravate these parameters and cognitive decline in HFD-fed rats. These results suggest that aging, obesity, and combined model have equally adverse effects on cognition. These findings can be used to increase public awareness of the negative impact of both aging and obesity on neurodegeneration.Entities:
Keywords: Aging; Cognition; Microglia; Obesity; Synaptic plasticity
Mesh:
Substances:
Year: 2020 PMID: 32522583 DOI: 10.1016/j.exger.2020.111001
Source DB: PubMed Journal: Exp Gerontol ISSN: 0531-5565 Impact factor: 4.032